Actionable news
All posts from Actionable news
Actionable news in ADAP: Adaptimmune Therapeutics PLC,

Adaptimmune Receives Orphan Drug Designation in the European Union for its NY-ESO SPEAR® T-cell Therapy for Treatment of Soft Tissue Sarcoma

PHILADELPHIA and OXFORD, United Kingdom, July 26, 2016 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (ADAP), a leader in T-cell therapy for treatment of cancer, today announced that the European Commission has designated the company’s NY-ESO SPEAR® T-cell therapy as an orphan medicinal product for the treatment of soft tissue sarcoma, a solid tumor cancer.

Adaptimmune previously received orphan drug destination from the U.S. Food and Drug Administration for its NY-ESO SPEAR T-cell therapy in this indication.

“We are delighted to have received the European Commission’s orphan medicinal product designation,” said Dr. Rafael Amado, Adaptimmune’s Chief Medical Officer. “We look forward to progressing our NY-ESO SPEAR T-cell therapy through clinical trials with the goal of eventually making this product available in Europe to patients with advanced soft tissue sarcoma.”

Orphan drug designation by the European Commission provides certain regulatory and financial incentives for companies to develop and market therapies that treat a life-threatening or chronically debilitating condition affecting no more than five in 10,000 persons in the European Union (EU), and where no satisfactory treatment is available. The designation provides incentives for companies seeking protocol assistance and scientific advice from the European Medicines Agency (EMA) during the product development phase and a 10-year period of marketing exclusivity in the EU following product approval.

Data from recent published epidemiological studies estimate the prevalence of soft tissue sarcoma in the EU to be 2.86 per 10,000 which corresponds to approximately 146,918 people based on the total population of 513.7 million people in the EU, Norway, Iceland, and Liechtenstein as of January 1, 2015 [EUROSTAT 2015].

The European Commission’s...